Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Medigene AG. (1/7/16). "Press Release: Medigene to Participate at Three International Conferences". Martinsried.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 J.P. Morgan Investment Management Inc.
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 34th Annual Healthcare Conference 2016 San Francisco
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index term Index term Medigene–JPMorgan Chase: investor conference, 201601 supply service Medigene participates at JP Morgan Healthcare Conference 2016
Persons Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
  Person 2 Mayer, Robert (Medigene 201512– Senior Manager PR + IR before College Hill Life Sciences/Northbank Munich)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at three upcoming conferences:

J.P. Morgan 34th Annual Healthcare Conference

Date: 11 - 14 January 2016
Location: San Francisco, CA, USA

Phacilitate Cell & Gene Therapy World

Date: 25 - 26 January 2016
Location: Washington DC, USA
Prof. J. Dolores Schendel, CSO and designated CEO of Medigene will speak on 26 January, 2.45 - 3.05 pm on the following topic: "Tailoring immunotherapies of cancer for stage and type of disease"

The 2nd Biologics and Biosimilars Congress

Date: 1 - 2 February 2016
Location: Berlin, Germany
Medigene will present on 2 February, 2.35 - 3 pm on the following topic: "TCR gene therapy: Developing technologies for now and the future: Essentials needed for a TCR tool box"

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01, Email:

Record changed: 2017-07-02


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top